Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Up 30.2% in March

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 16,400 shares, a growth of 30.2% from the February 28th total of 12,600 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average trading volume of 77,600 shares, the short-interest ratio is presently 0.2 days.

Global X Genomics & Biotechnology ETF Stock Down 1.4 %

Shares of NASDAQ GNOM traded down $0.11 during trading on Tuesday, reaching $7.84. 53,761 shares of the company traded hands, compared to its average volume of 61,847. The firm has a 50 day simple moving average of $9.41 and a 200-day simple moving average of $10.12. Global X Genomics & Biotechnology ETF has a 52-week low of $7.84 and a 52-week high of $11.88. The stock has a market capitalization of $54.64 million, a PE ratio of -3.35 and a beta of 1.03.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new position in shares of Global X Genomics & Biotechnology ETF in the 4th quarter worth $2,974,000. Portland Global Advisors LLC grew its stake in shares of Global X Genomics & Biotechnology ETF by 3.6% during the 4th quarter. Portland Global Advisors LLC now owns 268,988 shares of the company’s stock valued at $2,612,000 after purchasing an additional 9,373 shares during the period. Jane Street Group LLC increased its position in shares of Global X Genomics & Biotechnology ETF by 4.9% during the 4th quarter. Jane Street Group LLC now owns 133,405 shares of the company’s stock valued at $1,295,000 after purchasing an additional 6,221 shares during the last quarter. Two Sigma Investments LP lifted its stake in shares of Global X Genomics & Biotechnology ETF by 74.5% in the 4th quarter. Two Sigma Investments LP now owns 85,500 shares of the company’s stock worth $830,000 after purchasing an additional 36,500 shares during the period. Finally, Flow Traders U.S. LLC purchased a new position in shares of Global X Genomics & Biotechnology ETF in the third quarter worth approximately $936,000. Hedge funds and other institutional investors own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.